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A Way to Improve Secondary Prevention in Patients After
Percutaneous Coronary Intervention?*Kurt Huber, MDC urrent European Society of Cardiologyguidelines recommend prasugrel or ticagre-lor over clopidogrel in patients with acute
coronary syndromes (ACS) after percutaneous inter-
vention (PCI) (1). Despite this clear recommendation,
a signiﬁcant percentage of patients do not beneﬁt
from more effective P2Y12 inhibition because many
patients receive clopidogrel as ﬁrst-line therapy,
frequently pre-hospital, without further attempt to
switch to the more effective agents (2). Reasons for
this situation include potential warnings against pra-
sugrel, for example, higher age (>75 years) and/or low
body weight (<69 kg). Another reason is the fear of
inducing more bleeding complications when a switch
from full-dose clopidogrel to full-dose prasugrel or
ticagrelor is performed.SEE PAGE 1563In this issue of JACC: Cardiovascular Inter-
ventions, Valenti et al. (3) report a signiﬁcant
reduction of long-term cardiovascular mortality and
stent thrombosis in all-comers undergoing PCI (42%
ACS patients) as compared with a historical patient
cohort of clopidogrel nonresponders (100% ACS
patients), when clopidogrel treatment was switched
to prasugrel in nonresponders to clopidogrel based
on platelet function testing (PFT) by use of
light transmission aggregometry (LTA) (RECLOSE-3
[REsponsiveness to CLOpidogrel and StEnt Throm-
bosis] trial).*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the 3rd Department of Internal Medicine, Cardiology and Intensive
Care Medicine, Wilhelminenhospital, Vienna, Austria. Dr. Huber has
received lecture and consultant fees from AstraZeneca, Eli Lilly and
Company, Merck, Sanoﬁ Synthelabo, and The Medicines Company.CLOPIDOGREL RESPONSE VARIABILITY
A reduced action of clopidogrel, leading to high
on-treatment platelet reactivity (HTPR), has been
described in up to 30% of patients and is due to
clinical factors including poor absorption, drug–drug
interactions, ACS, diabetes mellitus, and chronic
kidney disease; genetic factors (certain CYP poly-
morphisms); and cellular factors such as accelerated
platelet turnover, reduced CYP3A4 metabolic activity,
or up-regulation of P2Y12 pathway, respectively (4).
HIGH OR LOW ON-TREATMENT PLATELET
REACTIVITY MAY CAUSE ISCHEMIC OR
BLEEDING EVENTS
As extensively analyzed and reported in the past,
HTPR on dual antiplatelet therapy with aspirin and
clopidogrel is usually related to an increase in stent
thrombosis and other ischemic events, whereas a
low on-treatment platelet reactivity reﬂects hyper-
responsiveness to clopidogrel and may be related to
bleeding hazards (5).
FREQUENCY, SAFETY, AND EFFICACY OF A
SWITCHING STRATEGY
A recent analysis from the U.S. national data registry
revealed that only up to 7% of patients on clopidogrel
were switched to prasugrel, which is far below the ex-
pected rate of low- or nonresponders to clopidogrel (6).
In an observational, nonrandomized study of
ST-segment elevation myocardial infarction patients,
the administration of a loading dose of prasugrel in
patients pre-treated with a loading dose of clopidogrel
was not associated with an excess of major bleeding
events (7). In a meta-analysis of 12 studies involving
3,956 patients, 35.3% received prasugrel after clopi-
dogrel treatment. Mortality and other secondary
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1572efﬁcacy endpoints were numerically, but nonstatisti-
cally, lower in those patients, and major bleedings
were similar, compared with standard therapy (8).
PERSONALIZED ANTIPLATELET STRATEGIES
AND CLINICAL OUTCOME?
Three large-scale randomized clinical trials in this
ﬁeld have failed to demonstrate any beneﬁt of
tailored antiplatelet therapy (9–11). In the GRAVITAS
(Gauging Responsiveness with A VerifyNow Assay–
Impact on Thrombosis And Safety) trial, standard-
versus high-dose clopidogrel was investigated based
on PFT after PCI without clinical beneﬁt for increa-
sing the dosage (9). The ARCTIC (Assessment by a
Double Randomization of a Conventional Antiplatelet
Strategy versus aMonitoring-guided Strategy for Drug-
Eluting Stent Implantation and of Treatment Inter-
ruption versus Continuation One Year after Stenting)
trial showed no signiﬁcant improvements in clinical
outcomes with PFT and treatment adjustment for
coronary stenting (additional bolus of clopidogrel,
prasugrel, or aspirin along with glycoprotein IIb/IIIa
inhibitors during the procedure), as compared with
standard antiplatelet therapy withoutmonitoring (10).
Finally, in the TRIGGER (Testing Platelet Reactivity
In Patients Undergoing Elective Stent Placement on
Clopidogrel to Guide Alternative Therapy With Prasu-
grel) trial, switching from clopidogrel to prasugrel in
patients with HTPR led to effective platelet inhibi-
tion, but given the low rate of adverse ischemic events
after PCI in stable coronary artery disease, the clinical
utility of this strategy could not be demonstrated (11).
It was discussed that similar clinical outcome data
between clopidogrel standard dose versus clopidogrel
increased dose or versus prasugrel was mainly due to
the majority of low-risk stable patients in these trials.
By contrast, it could be shown in the ISAR-HPR
(ISAR-High Platelet Reactivity) registry that reloading
with clopidogrel or use of prasugrel exhibited a sta-
tistical beneﬁt in 30-day all-cause mortality or stent
thrombosis, whereas bleeding was nonsigniﬁcantly
increased (12). Accordingly, it seems essential to
switch ACS patients with HTPR undergoing PCI on
clopidogrel to more effective agents. The study
design of the RECLOSE-3 study, despite having
almost 50% ACS patients versus 100% in the historical
control, has taken advantage of this knowledge (3).
ARE THE AVAILABLE TEST SYSTEMS
USEFUL FOR A PERSONALIZED
ANTIPLATELET STRATEGY?
Investigating PFT after switching from clopidogrel
to prasugrel has shown a signiﬁcant improvementof platelet function inhibition (13). There is still dis-
cussion about the most reliable platelet function
assay for clinical routine. In patients with ACS un-
dergoing PCI, signiﬁcant correlations exist between
LTA, VerifyNow, and VASP tests. Also, the multiple
electrode platelet aggregometry test, which is easy to
perform and inexpensive, gives comparable results
with other tests (4). LTA for clinical routine seems
less practicable because it requires a high degree of
expertise, misses a clear standardization, and does
not provide a generally accepted cutoff to determine
HTPR patients, which makes results between labora-
tories hardly comparable (4).CONCLUSIONS
It is essential to follow international guidelines in
ACS patients undergoing PCI, that is, either to use the
more effective P2Y12 inhibitors prasugrel or ticagrelor
as ﬁrst-line therapy, or to use clopidogrel ﬁrst,
perform PFT, and switch from clopidogrel to prasu-
grel (or ticagrelor) in case of HTPR. Such switching
strategy has so far not been successful in low-risk
patients, that is, in stable coronary artery disease
and planned PCI. Well-standardized platelet fu-
nction assays might offer an ideal tool for personal-
ized antiplatelet therapy. These assays might also
help to disclose the low percentage (up to 6%) of
nonresponders to prasugrel (14) and might help to
reach the optimal therapeutic range, covering efﬁ-
cacy and safety, because personalized antiplatelet
therapy was even superior to a strategy with empiric
ticagrelor (15). Whether personalized antiplatelet
therapy based on PFT will inﬂuence routine mecha-
nisms in the near future is a topic of current inves-
tigation in the prospective, randomized TROPICAL
ACS trial (Testing Responsiveness to Platelet Inhibi-
tion on Chronic Antiplatelet Treatment For Acute
Coronary Syndromes Trial; NCT01959451).
Whether all these efforts to optimize antiplatelet
therapy with P2Y12 inhibitors are sufﬁcient is still a
matter of debate because the pathology of thrombosis
is a complex interplay between cellular (i.e., plate-
lets) and plasma components (i.e., coagulation fac-
tors), as for example thrombin, which is one of the
strongest stimuli for platelet activation and not
inhibited by P2Y12 antagonists.
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